LA-PEG-G molecule was prepared through the covalent conjugation of linoleic acid, polyethylene glycol and guanosine. LA-PEG-G molecule can self-assemble into spherical aggregate in aqueous solution. The size of the LA-PEG-G aggregate was approximately 132.1 ± 13.718 nm, and the Zeta potential was −36.3 ± 0.9644 mv. The loading rate of LA-PEG-G aggregates to Dox was 84.62 ± 1.810%. In vitro release experiments showed that Dox release from the LA-PEG-G-Dox nanomedicine was slow-release. Cell experiments showed that LA-PEG-G aggregates have low cytotoxicity, and the relative cancer cells survival rate decreased with the increasing of time and LA-PEG-G-Dox nanomedicine concentration. In vivo experiments showed that LA-PEG-G-Dox nanomedicine can inhibit tumor growth, and the LA-PEG-G aggregate could also delay the tumor growth which is very important to play the synergistic antitumor effect with the anticancer drug. Serum biochemistry showed that LA-PEG-G-Dox nanomedicine which reduced the Dox toxicity had very good antitumor effect. The tumor tissue sections indicated that LA-PEG-G-Dox nanomedicine can effectively induce tumor cell apoptosis, and finally cause tissue necrosis to achieve tumor treatment.
growth of tumor cells, but damaged tumor cells still differentiate faster than normal cells. Moreover, the side effects of chemotherapy are seriously large and toxic due to the nonspecificity treatment of anticancer drugs. Therefore, new green therapies need to be discovered to reduce the side effects of traditional cancer treatment is an urgent problem to be solved [2] . Various drug carriers provide a solution to the above problems [3] [4] [5] [6] . Drug carriers can change the pharmacokinetic properties of the chemotherapy drug. For example, it can improve the water solubility of the drug, prolong the systemic circulation time, and avoid nonspecific uptake and preferential accumulation of tumor sites by enhancing osmotic and retention effects [7] .
The materials used in drug carriers affect the properties of drug carriers. Linoleic acid (LA) is a polyunsaturated fatty acid containing two unsaturated fatty chains with various good biological properties [8] [9] . In addition, polyunsaturated fatty acids have been found to have antitumor properties and sensitivity to cancer cells and exhibit potential tumor therapeutic effects. Polyethylene glycol (PEG) has excellent water solubility and biocompatibility and can significantly prolong the circulation time [10] in the body systemic circulation. PEG can form a water layer on the surface of the polymer, thereby increasing the stability of the polymer and reducing the adsorption of proteins in the body and reducing the recognition of the mononuclear macrophage system as much as possible. Long-circulating macromolecules and various long-circulating nanomedicines spontaneously accumulate in pathological areas (such as tissue sites) that have high permeation and retention effects (EPR effect) [7, 11] . Therefore, the PEG-modified aggregates easily aggregate at the tumor site, endowing the passive targeting effect of the aggregate. Guanosine (G) is an important extracellular signal molecule secreted by astrocytes. When the central nervous system is damaged, the extracellular G concentration in this region is instantly increased, and a variety of important cellular pathways are activated to counteract brain damage [12] [13] [14] [15] [16] .
In addition, G can regulate the metabolism of glutamate and avoid the excitatory poisoning caused by excessive excitation of glutamate receptors. Simultaneously, the anti-oxidation and anti-inflammatory effects of G can regulate a variety of cellular pathways to protect the central nervous system [17, 18] . Further studies found that the nutritional and central defense function of G can also alleviate chronic diseases such as depression and Parkinson's disease [19] .
In the present study, the LA-PEG-G was prepared through the covalent conjugation of LA, PEG, and G molecules (Scheme 1). The LA-PEG-G molecules can self-assemble into spherical aggregates in aqueous solution, and the potential targeting of LA combined with the EPR effect of PEG can increase the targeting and prolong the cycle time of LA-PEG-G aggregate. The spherical LA-PEG-G aggregates can load the lipophilic anticancer drugs. Dox was used as a drug model to obtain LA-PEG-G-Dox nanomedicine. Dox release from the LA-PEG-G-Dox nanomedicine was pH-responsive and slow-release. Moreover, in vivo and in vitro experiments showed that the LA-PEG-G-Dox nanomedicine can induce apoptosis in the cell of tumor tissue to inhibit tumor growth and metastasis. The LA-PEG-G drug carrier adds new impetus to the development of drug delivery systems and is expected to contribute to clinical applications. Scheme 1 LA-PEG-G molecules self-assemble into spherical aggregates that are used as drug delivery systems for tumor treatment.
Experimental and Methods

Synthesis of LA-PEG Molecules
The LA (0.08797 mL, 0.2830 mmol. J&K Scientific, China) was dissolved in 15 mL anhydrous THF while stirring. Then, DCC (0.03396 mmol. N, N′-dicyclohexylcarbodiimide) and NHS (0.03396 mmol. N-hydroxysuccinimide) were added into the above THF solution and dissolved while stirring for 24 h at room temperature. After the prescribed time, 15 mL of DMF which contained PEG (1-amino-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid) at 100 mg (0.2830 mmol) was added into the above THF mixture and then reacted for 48 h while stirring at room temperature. Then, the mixture solution was filtered to remove any solid matter, and the solution was retained and subjected to freeze-drying treatment to obtain a white LA-PEG crude powder(Scheme 2). The LA-PEG crude powder was purified by silica gel column chromatography with the mobile phase of dichloromethane and methanol, and the elution of 97 to 3 (Dichloromethane to methanol) was collected.
The elution was then freeze-dried to give a pale yellow LA-PEG powder pure sample.
Synthesis of LA-PEG-G Molecules
G (2',3'-isopropylidene Guanosine; 100.6246 mg, 0.283 mmol) was dissolved in 15 mL anhydrous DMF. Then, DIPEA (283 μL), DMAP (0.03457 g, 0.283 mmol) and EDC (0.05425 g, 0.2830 mmol) was added while stirring. The LA-PEG sample was firstly dissolved in 15 mL of anhydrous DMF. Then, the LA-PEG DMF solution was mixed with the above G mixture solution and then stirred for 48 h at room temperature [20] (Scheme 2). The crude product of LA-PEG-G was obtained and purified by alkaline alumina column chromatography with the mobile phase of methanol to ethyl acetate. The elution solution of 1:1 (Methanol: ethyl acetate) was collected and then lyophilized to obtain the pure sample LA-PEG-G molecules.
Scheme 2
The synthetic process of LA-PEG-G molecules
Determination of Critical Aggregation Concentration of LA-PEG-G
Aggregates LA-PEG-G can self-assemble to form aggregates in aqueous solution. The critical aggregation concentration (CAC) measurement of aggregates was carried out by the fluorescence probe method to study the aggregation process of LA-PEG-G in water.
The pyrene fluorescent probe is a hydrophobic molecule. The fluorescence spectrum of the pyrene molecule has a significant change in different solvents, and the CAC value [21] is judged based on the significant change of the fluorescence spectrum.
Pyrene was dissolved in acetone to prepare a mother liquor of 50 μL 6×10 -6 mol·L -1 , which was added to nine volumetric flasks (10 mL) . Then, a series concentration of LA-PEG-G aggregate solution was added to the volumetric flask. Finally, the solution was filled to the mark with distilled water. The concentration of the LA-PEG-G aggregate solution was 1×10 -6 -1×10 -1 mg·mL -1 , and then sonicated for 30 min, and then incubated for 30 min at 50 °C. Finally, the fluorescence spectrum (LS-55, PerkinElmer, UK) was measured, and the excitation and emission wavelength was 295 and 339 nm respectively. Moreover, the excitation and emission slit was 5 and 2.5 nm, respectively. The CAC value [21] was determined by the change of the ratio of I371 (I refers to fluorescence intensity) to I391 in the fluorescence spectrum [21] .
Morphology Observation of LA-PEG-G Aggregates and the Determination of Particle Size and Zeta Potential
LA-PEG-G molecules can self-assemble to form aggregates in water. The particle size and morphology were determined to verify the distribution in LA-PEG-G aggregates. The morphology of LA-PEG-G aggregates was characterized by TEM (Transmission electron microscopy. JEM-1400, JEOL, Tokyo, Japan). The LA-PEG-G aggregate solution was dropped onto the copper mesh with carbon support film and kept on the copper mesh for 2 min. The liquid on the copper mesh was sucked off from the filter paper on one side. Then, the aggregates on the copper mesh were subjected to negative staining with 1 % phosphotungstic acid. The copper mesh was placed under the infrared lamp for drying treatment after negative dyeing, and TEM characterization [22] was performed. The particle size and Zeta potential of the aggregates were measured by a Marvin particle sizer (Zeta sizer Nano ZS, UK).
Preparation of LA-PEG-G-Dox Nanomedicine and Determination of Encapsulation Efficiency
1 mg Doxorubicin (Dox) was added into 10 mL methanol. Then, 480 μL triethylamine (The molar ratio of Dox to triethylamine is 1 to 2) was added while stirring for 6 h in the dark place. Then, the methanol solution which contained 1 mg LA-PEG-G sample was added to the above mentioned mixture solution with stirring and then incubated for 30 min at 50 °C. After the prescribed time, the methanol was removed by using a rotary evaporator. The mixture was then mixed with 25 mL of distilled water, sonicated for 1 h, and then centrifugated (12 000 rpm, 5 min). The absorbance intensity of the supernatant was determined with the ultraviolet-visible (UV-vis) spectrophotometer (The measuring wavelength is 485 nm), and the encapsulation efficiency was calculated according to the Dox standard absorption curve. The encapsulation rate calculation formula is as follows:
where Csup is the concentration of Dox in the supernatant solution and Ctol is the total concentration of Dox.
The Release Behavior of Dox from the LA-PEG-G-Dox Nanomedicine
Dox is a broad-spectrum anticancer drug which can inhibit the synthesis of RNA and DNA through intercalating nucleic acid. Therefore, whether Dox can be released from LA-PEG-G-Dox nanomedicine is a prerequisite for Dox to function. Therefore, studying the in vitro release of Dox from the LA-PEG-G-Dox nanomedicine is necessary. The infinite proliferation of tumor cells leads to hypoxia in tumor tissues, and glycolysis produces a large amount of lactic acid in an anaerobic state. Therefore, the pH in tumor tissues is lower than that in normal tissues. Hypoxia and acidic microenvironment become prominent features of tumor tissue [23] . According to the micro-acid environment of the tumor tissue, the pH-targeting carrier can be designed to make the Dox, which enters and accumulates primarily in the tumor tissue to better exert the antitumor effect. The release behavior of Dox from the LA-PEG-G-Dox nanomedicine at pH 5.0 and 7.4 was investigated to study the effect of tumor microenvironment on the release behavior. The amount of Dox released was measured at 37 °C. Buffer solution (4 mL) was taken out from the buffer solution outside the dialysis bag for UV-visible spectrophotometer detection (detection wavelength is 485 nm) at different times (1, 2, 4, 8, 12, 24, 36, 48, 72, 84, 96, 108 , and 120 h), whereas 4 mL fresh buffer solution was added into the buffer solution outside the dialysis bag.
The released Dox concentration was calculated according to the standard curve of Dox, and the cumulative release amount was finally calculated according to the following formula:
In this equation, ni is the fold of dilution, Ci is the DOX concentration in each sample, V means the medium volume (20 mL), Vextract is sample volume (1.0 mL), and W represents the total amount of Dox.
Cell culture
The human liver cancer (HepG2 cells) and breast cancer cell lines (MCF-7 cells)
were selected as experimental cell models to analyze the cytotoxicity of LA-PEG-G aggregates and the anticancer activity of LA-PEG-G-Dox nanomedicines. Both cells were obtained from the experiment center of Binzhou Medical University. HepG2 and MCF-7 cells were incubated in DMEM high-glucose culture medium, which contained 10 % fetal bovine serum and 1 % penicillin and streptomycin (penicillin, 100 U·mL -1 ; streptomycin, 0.1 mg·mL -1 ) in 5 % CO2 atmosphere at 37 °C. Untreated cells served as control group. The cells were then placed in an incubator to incubate for 24 h. After 24 h, MTT was added to 96-well plate at 10 μL per well and incubated for another 4 h. After the prescribed time, all the old culture solutions in each well were removed. Then, 150 uL of DMSO was added to each well, and the 96-well plate was shaken for 10 min in the dark. Finally, the absorbance intensity was determined with the microplate reader at detection wavelength of 570 nm. The cell survival rate is calculated as follows:
Cell Cytotoxicity of LA-PEG-G Aggregates and the Anticancer Activity of
LA-PEG-G-Dox Nanomedicine
Cell survival rate (%) = OD treated OD control × 100%
Where ODtreated and ODcontrol are the absorbance intensities for the experimental group and control group, respectively. Each sample was determined three times.
Cell Uptake
Laser-Scanning Confocal Microscopy (LSCM)
HepG2 cells were chosen as experimental model cells to study the uptake of LA-PEG-G-Dox nanomedicine by cancer cells. HepG2 cells were seeded in 6-well plates (The number of cells per well was approximately 1×10 -5 ) and then mixed with 2 mL culture medium containing 10% fetal bovine serum and 1 % penicillin and streptomycin per well. The cells were cultured overnight in 5 % CO2 incubator at 37 °C until the cells adhered, and the old culture solution was removed.
LA-PEG-G-Dox nanomedicine was added, and the final concentrations were 10μg·mL -1 and 20 μg·mL -1 . Cells were cultured for 4 h, 8 h, and 24 h respectively.
After the prescribed time, the old culture solution was removed and washed there time with PBS (1×) to prevent the excess LA-PEG-G-Dox nanomedicine in the plate from affecting the experimental results. Finally, 2 mL of the fresh culture medium was added. The Petri dishes were transferred to laser-scanning confocal microscopy (LSCM, EPICS XL, Beckman, USA) for measurement. The excitation and emission wavelengths were 488 nm and 590 nm nm respectively.
Flow Cytometry (FCM)
LSCM can qualitatively study the uptake of LA-PEG-G-Dox nanomedicine in cancer cells. Flow cytometry (FCM) was used to further quantitatively study the uptake of LA-PEG-G-Dox nanomedicine in cancer cells. HepG2 cells were seeded in 6-well plates (the number of cells per well was approximately 1×10 5 ), and then, 2 mL culture medium containing 10 % fetal bovine serum and 1 % penicillin and streptomycin was added to each well. The cells were cultured overnight in a 5 % CO2 incubator at 37 °C until the cells adhered, and the old culture medium was removed.
Then, the LA-PEG-G-Dox nanomedicine was added, and the final concentrations were 10μg·mL -1 and 20 μg·mL -1 . The cells were then cultured for 4 h, 8 h, and 24 h.
After the prescribed time, the old culture medium was removed and then washed three time with PBS (1×). 1 mL Trypsin was added to each well to digest the cells. After 2 min, the collected old culture solution was added to prevent digestion and gently triturated to make the cell suspension. The cells were transferred to a flow tube for FC determination (TCS SPE, Leica, Germany). The excitation and emission wavelengths were 488 and 590 nm respectively.
Animal Experiment and Blood Chemistry
Ethics approval and consent to participate: The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of Binzhou Medical University. Written informed consent was obtained from individual or guardian participants.
Antitumor Activity of LA-PEG-G-Dox Nanomedicine in Mice
Tumor-bearing mice were used as experimental models to further study the antitumor effect of LA-PEG-G-Dox nanomedicine in vivo. All the mice (30-35 g) used in the trial were female and housed under the "Guidelines for the Care and Use of Test Animals." When the mice growed for 4-6 weeks, the left forelimb was depilated to expose, and then H22 cells (1×10 6 ) were injected into the left subcutaneous forelimb.
The following experiment was carried out when the tumor volume has grown to 100-200 mm 3 . The mice were randomly divided into four groups, namely, the PBS group, Dox group, LA-PEG-G aggregate group, and LA-PEG-G-Dox nanomedicine group. The PBS (0.2 mL), Dox (15 mg·kg -1 ), LA-PEG-G aggregate (15 mg·kg -1 ), and LA-PEG-G-Dox nanomedicine (15 mg·kg -1 ) were injected separately into the mice body through the tail vein injection every other day. The mice body weight were weighed before injection, and the mice volume was also measured with a vernier caliper. The mice blood were obtained by using the neck-breaking method at the end of the experiment. The tumor, heart, liver, spleen, lung, and kidney were dissected. All dissected tissues were immediately placed in paraformaldehyde (4 %) to fix for 48 h.
After the prescribed time, the tissues were dehydrated, embedded in paraffin, sliced, and then stained with Hematoxylin-Eosin (HE).
Blood Serum Chemistry
After 19 days injection to the mice, the whole-body blood was collected through the neck-breaking method. The blood was allowed to coagulate for 20-30 min at room temperature and then centrifuged at 3500 r/min for 5 min. The supernatant was collected to execute the analysis of the liver function, renal function, and myocardial enzyme.
Statistical Analysis
Statistical analysis was performed using the Student t-test. The significance level was set as p < 0.05.
Results and Discussion
Synthesis, Characterization, and Aggregation Behavior of LA-PEG-G Molecules
The pure LA-PEG-G sample was obtained through the purification of column chromatography. Thin-layer chromatography was used to preliminarily analyze the LA-PEG-G sample. The Rf value of LA-PEG-G sample was obviously different from those of LA, DCC, NHS, and PEG molecules as shown in Figure S1 , which preliminarily proved that the sample was the LA-PEG-G sample. The LA-PEG-G molecules were characterized through the FT-IR (Fourier transform infrared spectroscopy), nuclear magnetic resonance (NMR) and mass spectrometry (MS) methods. As seen from the FT-IR spectrum (Figure S2) , the 1568 cm -1 peak was the characterization of stretching vibration of -C=Cgroup of LA molecules, and the 648 cm -1 peak was the cis-hydrocarbon stretching vibration peak of -C=Cgroup of LA molecules, and the peak at 3435 cm -1 was the stretching vibration of -NHgroup of G, and the peak at 1614 cm -1 was the stretching vibration peak of the carbonyl bond of PEG molecules. The above FT-IR results showed that the LA-PEG-G molecules were successfully synthesized. As shown in the NMR spectrum ( Figure S3 ), δ 8.56 was the H shift of -NHgroup in G, and δ 7.81 was the H shift of -NHgroup, which was formed by the LA and PEG molecules, respectively. Moreover, δ5.58-4.40 was the H shift on the side chain of five-membered ring of G, and δ 4.90 was the H shift of -NH2 group in G. All NMR data showed that the LA-PEG-G molecules were successfully synthesized. The MS spectrum showed that the 964.36 (m/z) peak was the negative ion peak of [M+HCOOH] -, thereby indicating that the LA-PEG-G molecules had been successfully synthesized. In summary, the NMR spectrum and MS proved that LA-PEG-G molecule had been successfully synthesized. The successful synthesis of LA-PEG-G molecules was the prerequisite for further experiment.
LA is a typical fat-soluble molecule, and PEG is a hydrophilic polymer, which make the LA-PEG-G molecule exhibit both lipophilic and hydrophilic properties.
The property of the LA-PEG-G molecule allows it to self-assemble into spherical aggregates in water. The CAC value of the LA-PEG-G molecules was 2.512×10 -3 mg·mL -1 (Figure S5) . The morphology of LA-PEG-G aggregates was observed with the TEM and FF-TEM (Freeze-fracture TEM), as shown in Figure 1a and 1b. The LA-PEG-G aggregates exhibited a spherical structure with uniform shape and distribution without aggregation. The size of LA-PEG-G aggregates was about 40 nm, as shown in the Figure 1b . However, the results of Malvern particle size analyzer showed that the size of the LA-PEG-G aggregates in aqueous solution was 132.1 ± 13.72 nm as shown in Figure 1c . The hydration radius of LA-PEG-G aggregates is the size difference to the results of FF-TEM. The size of aggregates allows easy accumulation in the tumor tissue through the EPR effect. The Zeta potential of the LA-PEG-G aggregates was −35.80 mV in the aqueous solution, which indicated that the surface of the LA-PEG-G aggregates was negatively charged in aqueous solution. A high Zeta potential allows the LA-PEG-G aggregates to maintain good dispersion in aqueous solution [24, 25] . The PEG in the LA-PEG-G molecules can help the LA-PEG-G aggregates escape from the trap of Kupffer cells and macrophages in the spleen through scavenger receptors without activating MPS, which help the blood circulation of the LA-PEG-G aggregates in the body [25] . 
Dox-Loading Ratio of LA-PEG-G Spherical Aggregates and Dox Release
Behavior from the LA-PEG-G-Dox Nanomedicine
Dox is a broad-spectrum antitumor antibiotic which can insert into DNA helical double chain and thereby affects DNA transcription and protein synthesis, which cause the strong toxicity (Such as cardiotoxicity, nausea, and loss of appetite) [26] . The encapsulation of LA-PEG-G aggregates to Dox decreases its toxicity, and improves its water solubility, and facilitates its intravenous injection. The encapsulation results 
Cytotoxicity of the LA-PEG-G Aggregates and Anticancer Effect of the
LA-PEG-G-Dox Nanomedicine in In Vitro
In vitro release experiments showed that Dox can be slowly released from the 
Cell Uptake
HepG2 cells was used to study the cell uptake of LA-PEG-G-Dox nanomedicine with the LSCM and FCM [27] . Figure 4c) . However, the higher LA-PEG-G-Dox nanomedicine concentration (20 μg·mL -1 ) can rapidly enter into the cytoplasm and nucleus, and the fluorescence intensity was also higher than that of 10 μg·mL -1 LA-PEG-G-Dox nanomedicine group, as shown in Figures 4d, 4e, and 4f .
Simultaneously, the cell morphology also changed, and the cells became round and condensed. Apoptosis gradually occurred. FCM assay was performed to quantify the cell uptake of the LA-PEG-G-Dox nanomedicine to further verify the cellular uptake. 
Antitumor Activity in Vivo and Blood Chemistry
The in vivo antitumor activity of LA-PEG-G aggregates and LA-PEG-G-Dox nanomedicine was further studied with tumor-bearing mice [29] . The tumor-bearing mice were randomly divided into four groups with five mice each group. Every mouse was numbered for subsequent animal experiments. The PBS, LA-PEG-G aggregate solution, and LA-PEG-G-Dox nanomedicine solutions were injected into the tumor-bearing mice through the tail vein. The body weight and tumor volume of mice were measured to observe the change of body weight and volume of mice after the injection. The tumor volume of PBS (Figures 5a and 5e ) and LA-PEG-G aggregate group (Figures 5b and 5f ) became significantly larger than the LA-PEG-G-Dox (Figures 5c and 5g) and Dox group (Figures 5d and 5h) The tumor and other important organs of mice were studied through the histological section, as shown in Figures 5k-5n . Seen from the HE staining results of mouse tumor tissues (Figures 5k-5n) , the cells of the tumor tissue sections of the PBS group and LA-PEG-G aggregate group grew vigorously, but tissue necrosis also occurred. The reason may be that the tissue necrosis was caused by insufficient blood supply from tumor growth. Compared with the PBS group (Figure 5k) , the range of tumor necrosis increased in the LA-PEG-G aggregate group (Figure 5l ), which indicated that the LA-PEG-G aggregate had a certain effect of inhibiting tumor growth [26] . However, LA-PEG-G-Dox nanomedicine (Figure 5m ) and Dox group The deposition of hemosiderin appeared, and it indicated that the Dox had serious toxic side effects to the spleen. In summary, the tissue sections showed that the LA-PEG-G-Dox nanomedicine can reduce the toxicity of Dox and induce tumor cell apoptosis, and further lead to tumor necrosis to play the antitumor effect. The mice plasmas were collected by the neck-breaking method and then centrifuged to determine the serum biochemistry, and the results were shown in Table  1 . Seen from the Table 1 , liver function test showed that alanine aminotransferase (ALT), albumin (ALB), and total bilirubin (TBIL) of the PBS group were lower than other groups, which indicated that the growth of solid tumor did not cause the damage of liver. In contrast, the three indicators of the Dox group were higher than the other groups, and it indicated that the Dox group caused serious damage to the liver of mice due to toxic side effects. Globulin changes in all groups were not obvious, which indicated that the tumor had no effect on the immune system of mice. The three indicators of LA-PEG-G group (ALT, ALB, and TBIL) were higher than PBS group and lower than the Dox group, and it indicated that the toxicity of LA-PEG-G was low. Moreover, LA-PEG-G-Dox group data showed that the LA-PEG-G-Dox can reduce the Dox toxicity of the liver. The renal function test showed that the solid tumor did not cause renal damage in the PBS group, and the DOX group had the highest urea nitrogen (BUN) and uric acid (UA) content due to the side effects of renal dysfunction. The content of BUN and UA of the LA-PEG-G and LA-PEG-G-Dox groups was lower than that the DOX group, and it suggested that LA-PEG-G-Dox nanomedicine reduced the Dox toxicity to kidney.
LA-PEG-G-Dox nanomedicine exerted anticancer effect while protecting the kidneys. The myocardial enzyme test data showed that although the Dox group had an antitumor effect, it had severe cardiotoxicity. In addition, the PBS group had a higher content of AST and α-HBDH due to the growth of solid tumors. The contents of AST and α-HBDH in LA-PEG-G-Dox and LA-PEG-G group were significantly lower than those in PBS and Dox group, and it indicated that LA-PEG-G-Dox nanomedicine reduces the cardiotoxicity of Dox and has an antitumor effect. In summary, the serum biochemical tests showed that LA-PEG-G-Dox nanomedicine can reduce Dox toxic side effects and have good antitumor effect. 
Conclusion
The amphiphilic molecule LA-PEG-G was synthesized as a drug carrier. This amphiphilic molecule can self-assemble to form aggregates in water with a particle size of 40 nm, which can aggregate at the tumor site to exert an antitumor effect. In vitro release experiments proved that Dox release from that LA-PEG-G-Dox nanomedicine was faster at pH 5.0 compared with pH 7.4, and which suggested that the LA-PEG-G-Dox nanomedicine have good pH-responsive release characteristics.
Cell experiments showed that the aggregates formed by LA-PEG-G molecules have extremely low cytotoxicity, and LA-PEG-G-Dox nanomedicine has good anticancer activity. In vivo experiments showed that LA-PEG-G aggregates have a certain inhibitory effect on tumor growth, and LA-PEG-G-Dox nanomedicine has a good therapeutic effect on tumors and almost no effect on the weight of mice. The serum biochemical test results suggested that LA-PEG-G-Dox nanomedicine can reduce the side effects of adriamycin on heart, liver, and kidney. In summary, the LA-PEG-G molecule is an ideal drug carrier, and the LA-PEG-G aggregates have important research significance in antitumor treatment.
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